We want survival in the UK to be among the best in the world. We’re focusing our efforts in four key areas – working to help prevent cancer, diagnose it earlier, develop new treatments and optimise current treatments by personalising them and making them even more effective.
We’ll continue to support research into all types of cancer and across all age groups. And we’re keeping our focus on understanding the biology of cancer so we can use this vital knowledge to save more lives.
We’re increasing our research in key areas such as early diagnosis, and hard-to-treat cancers including lung, pancreatic, oesophageal cancers and brain tumours.
We’re developing new tests, surgery and radiotherapy techniques, and cancer drugs. We want to personalise prevention, screening and treatment and bring benefits to patients sooner.
To help accelerate progress, we’ll be investing an additional £50 million a year into new funding schemes for our researchers. These will encourage collaboration and innovation, and support research tackling some of the biggest scientific challenges in cancer research.
Smoking is the biggest preventable cause of cancer and we’ll work towards the day when no one in the UK smokes – in particular by protecting children and helping people to quit.
We’ll campaign for the best cancer services in all parts of the UK, and give more people the chance to join the fight against cancer.
But we can’t achieve our mission alone. We rely on our dedicated scientists, doctors and nurses, and the generosity of our supporters across the UK. With your help, we can beat cancer sooner.
ClinoSol Provides Trainings and Resource consulting in the field of Clinical Research and Clinical Data Management.
Training and development play a pivotal role in the performance of organizations as well as the self-fulfilment of their employees. In the recent years, skilled and job-ready workforce for the corporate organizations, especially in a patient-centric world has become the need of the hour. ClinoSol, established in 2019, with its personalized gap-filling training structure sculptures the academic knowledge to the real-world skills in various most popular Clinical Research domains and connects these talents through our channelized resource consulting services across the nation and overseas.
The Imperial Clinical Trials Unit (ICTU) sits within Imperial College London as a department within the School of Public Health in the Faculty of Medicine and brings together academic, clinical and trial management expertise from across the Imperial College Academic Health Science Centre. ICTU also collaborates with members of the designated Academic Health Science Network for North West London – Imperial College Healthcare Partners, other national key clinical and scientific opinion leaders, other CTUs and with industry.
ICTU is a UKCRC registered Clinical Trials Unit recognised for its experience and expertise in the development and delivery of clinical trials and associated high quality clinical research projects across a range of therapeutic areas. The unit leads primarily on the design, conduct and analysis of national and international multi-centre trials and the staff, with specialist disease and methodological knowledge, have input at all stages of the trial lifecycle; thus ensuring all activities are conducted according to the principles of ICH GCP and in compliance with the appropriate regulatory and ethical requirements.
The ICR Clinical Trials and Statistics Unit (ICR-CTSU) is a research-led, academic clinical trials unit (CTU) within the Division of Clinical Studies at the ICR.
ICR-CTSU leads the design, conduct and analysis of phase II and III national and international cancer clinical trials. Our expertise spans the whole clinical trial life cycle and our findings directly influence clinical practice within the NHS and worldwide.
ICR-CTSU clinical trials focus on breast, urological and head and neck cancers, but we also run trials in other rarer cancer types including melanoma, sarcoma and ovarian cancer. We specialise in phase II exploratory and phase III randomised trials of new treatments and technologies (including radiotherapy), and understanding cancer biology and treatment response using biomarker-driven trial designs is fundamental to our research.
We receive core funding from Cancer Research UK, are a UK Clinical Research Collaborative (UKCRC) registered CTU and one of 15 CTUs recognised by the National Cancer Research Institute (NCRI) for professional specialism in the development and delivery of cancer trials.
The Medicines Evaluation Unit (MEU) Ltd is one of the UK’s leading contract research organisations, and a facility where commitment to excellence is paramount. Possessing extensive pharmaceutical, scientific and clinical expertise, allied with fast volunteer recruitment, both healthy and patient, within a state-of-the-art hospital based research facility, enables the MEU to offer clients positive clinical trial solutions.
The MEU’s bespoke database and trial management system I.C.A.R.U.S. assists recruitment of the right patient to the right study, facilitating rapid enrolment, allowing us to meet our clients’ timelines.
The MEU holds MHRA Phase I Accreditation, together with an MHRA Manufacturing Assembly Licence, enabling the company to perform assembly activities. We can also offer a full CRO service with our well-established partners.
The Peninsula Clinical Trials Unit (PenCTU) is a leading academic clinical trials unit, with expertise in designing, developing, supporting and co-ordinating high quality, multi-centre clinical trials and other well-designed studies that will directly influence clinical and healthcare practice.
PenCTU is a fully registered clinical trials unit in the UK Clinical Research Collaboration (UKCRC) and currently receives National Institute for Health Research (NIHR) CTU support funding. This funding has been awarded to support the Unit in developing and supporting NIHR research.
The PenCTU works in partnership with clinicians, researchers, the NIHR Research Design Service South West, the Clinical Research Network and other partners from across the South West Peninsula and beyond, starting with the funding application, to deliver the full spectrum of clinical trial expertise to applicable standards and regulations.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.